Therapeutics News and Research

RSS

MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines

New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.

14 Sep 2021

Colorectal Cancer Project launches to improve understanding of the disease and accelerate research

Count Me In, a nonprofit cancer research initiative, is inviting all patients across the United States and Canada who have ever been diagnosed with colorectal cancer to participate in research and help drive new discoveries related to this disease.

14 Sep 2021

Health leaders issue an urgent call for vaccine equity globally and in Africa

WHO Director-General Dr Tedros Adhanom Ghebreyesus and a group of global health leaders today issued an urgent call for vaccine equity globally and in Africa in particular.

14 Sep 2021

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

A synthetic molecular code shows promise towards improving the response of some cancer patients to immunotherapy treatments.

14 Sep 2021

Artemisia plant extract prevents SARS-CoV-2 replication in vitro

A new study describes the beneficial effect of an extract of Artemisia annua when used to treat cells in culture exposed to SARS-CoV-2.

13 Sep 2021

Study suggests SARS-CoV-2 circulation in schools is limited

A new study discusses existing evidence of SARS-CoV-2 transmission in an educational setting.

13 Sep 2021

Rutgers study examines link between COVID-19 and memory loss, dementia

A new Rutgers study will examine how COVID-19 is affecting individuals in a number of cognitive-related areas, including memory loss, "brain fog," and dementia.

13 Sep 2021

RNF5 protein plays an unusual role in acute myeloid leukemia, study shows

A new study led by scientists at Sanford Burnham Prebys has shown that the protein RNF5 plays an unusual role in acute myeloid leukemia (AML).

13 Sep 2021

MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors.

13 Sep 2021

Analysis finds untapped potential for immunotherapy in older cancer patients

A retrospective analysis of large datasets of biomarkers from tumors and healthy tissue by researchers at the Johns Hopkins Kimmel Cancer Center Convergence Institute suggests that older cancer patients could benefit as much as younger patients from cancer immunotherapies.

13 Sep 2021

Research suggests current smokers not at excess risk of SARS-CoV-2 infection

Now, a new study published on the bioRxiv* preprint server investigates this relationship further and suggests that current smoking is not associated with a higher incidence of SARS-CoV-2 infection.

13 Sep 2021

Researchers find a way to turn SARS-CoV-2’s virulence mechanism against itself

A recent study, currently available on the bioRxiv* preprint server, reveals that a specific region of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be targeted by antisense oligonucleotides to potently inhibit viral replication, and consequently the development of coronavirus disease (COVID-19).

12 Sep 2021

Does Delta increase the risk of hospitalization compared with Alpha?

A team of researchers conducted a cohort study to understand the risk of hospitalization in patients with either the Delta or Alpha variants of SARS-CoV-2.

12 Sep 2021

High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia

A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a highly aggressive cancer.

12 Sep 2021

Marshall University researcher awarded $1.36 million NIH grant for kidney-related study

Sandrine V. Pierre, Ph.D., associate professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine and interim director of the Marshall Institute for Interdisciplinary Research (MIIR), has been awarded a Research Project Grant (R01), one of the most competitive grants issued by the National Institutes of Health.

10 Sep 2021

Therapeutics News and Research

MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines

Colorectal Cancer Project launches to improve understanding of the disease and accelerate research

Health leaders issue an urgent call for vaccine equity globally and in Africa

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

Artemisia plant extract prevents SARS-CoV-2 replication in vitro

Study suggests SARS-CoV-2 circulation in schools is limited

Rutgers study examines link between COVID-19 and memory loss, dementia

RNF5 protein plays an unusual role in acute myeloid leukemia, study shows

MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

Analysis finds untapped potential for immunotherapy in older cancer patients

Research suggests current smokers not at excess risk of SARS-CoV-2 infection

Researchers find a way to turn SARS-CoV-2’s virulence mechanism against itself

Does Delta increase the risk of hospitalization compared with Alpha?

High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia

Marshall University researcher awarded $1.36 million NIH grant for kidney-related study

New center at UC San Diego to study the effects of antibiotics on mother’s milk and infant health

New statement on COVAX global supply forecast for 2021 and early 2022

Study identifies FDA-approved drugs that are effective in suppressing SARS-CoV-2 replication

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

New gene-delivering workhorse could make gene therapy safer, more effective for muscle diseases

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News